U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19NO3
Molecular Weight 237.2949
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VILOXAZINE

SMILES

CCOC1=CC=CC=C1OCC2CNCCO2

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI
Molecular Formula C13H19NO3
Molecular Weight 237.2949
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Unknown
99264
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7468
Inhibitor
7468
PubMed

PubMed

TitleDatePubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].
1986
[Apropos of atypical melancholia with Sustiva (efavirenz)].
2001 May-Jun
Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.
2002
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
2002
Simultaneous determination of viloxazine, venlafaxine, imipramine, desipramine, sertraline, and amoxapine in whole blood: comparison of two extraction/cleanup procedures for capillary gas chromatography with nitrogen-phosphorus detection.
2002 Jul-Aug
Intravenous antidepressant treatment: focus on citalopram.
2002 Jun
Tricyclic and related drugs for nocturnal enuresis in children.
2003
A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs.
2003 Oct
Contribution of sleep research to the development of new antidepressants.
2005
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
2005
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
2005 Dec 9
Internet-based search of randomised trials relevant to mental health originating in the Arab world.
2005 Jul 26
Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?
2005 Mar
Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome.
2005 Sep
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.
2006 Oct 20
Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma.
2007 Dec 28
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood.
2007 May
Antidepressant drugs for narcolepsy.
2008 Jan 23
Narcolepsy: current treatment options and future approaches.
2008 Jun
A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
2008 May
Adjustment Disorder: epidemiology, diagnosis and treatment.
2009 Jun 26
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.
2009 Nov
Getting the balance right: Established and emerging therapies for major depressive disorders.
2010 Sep 7
Patents

Patents

JP2006516976A
29

Sample Use Guides

In Vivo Use Guide
100 mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:32:50 UTC 2019
Edited
by admin
on Tue Oct 22 00:32:50 UTC 2019
Record UNII
5I5Y2789ZF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VILOXAZINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
VILOXAZINE [INN]
Common Name English
VILOXAZINE [WHO-DD]
Common Name English
VILOXAZINE [MI]
Common Name English
MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-
Systematic Name English
(+/-)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE
Common Name English
VILOXAZIN
Common Name English
VILOXAZINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06AX09
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
WHO-VATC QN06AX09
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
NCI_THESAURUS C265
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
Code System Code Type Description
MERCK INDEX
M11448
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY Merck Index
INN
3489
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
DRUG BANK
DB09185
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
ChEMBL
CHEMBL306700
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
WIKIPEDIA
VILOXAZINE
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
ECHA (EC/EINECS)
256-281-7
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
EPA CompTox
46817-91-8
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
MESH
D014745
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
CAS
46817-91-8
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
RXCUI
11196
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY RxNorm
PUBCHEM
5666
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
EVMPD
SUB00049MIG
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
NCI_THESAURUS
C152877
Created by admin on Tue Oct 22 00:32:50 UTC 2019 , Edited by admin on Tue Oct 22 00:32:50 UTC 2019
PRIMARY
Related Record Type Details
Structure of VILOXAZINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of VILOXAZINE, (R)-
ENANTIOMER -> RACEMATE
Structure of VILOXAZINE, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of VILOXAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966